Sermorelin 50microgram powder and solvent for solution for injection ampoules

Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and endotoxin burden of gray market research peptides using a large, publicly available independent testing dataset, and to compare their cost to compounded and FDA-approved alternatives. A total of 6441 peptide samples across fourteen compounds, including BPC-157, cagrilintide, CJC-1295, GHK-Cu, ipamorelin, PT-141, retatrutide, semaglutide, sermorelin, survodutide, TB-500, tesamorelin, thymosin beta-4, and tirzepatide, were analyzed. Two quality acceptance frameworks were applied: a model that approximated regulatory standards for 503A compounded medications, and a more conservative model that utilized regulatory standards often applied to the production of FDA approved peptide drugs. Between the two models, 41.6% to 71.1% of samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples. Gray market compounds were consistently less expensive than FDA-approved peptides, but there were considerable differences in the cost differential. Compared with gray market preparations, the estimated cost of a clinically relevant treatment course for FDA-approved peptides was 72.8% higher for tirzepatide, and 3850% higher for PT-141. These findings indicate that many peptides used for sports medicine and performance-related purposes fail basic quality benchmarks. Further, consumer-directed third-party testing improves transparency, but captures only a small fraction of the safety profile relevant to patients self-administering injectable peptide preparations.

Abstract licence: CC BY